Hypermarcas (OTCMKTS:HYPMY) Stock Falls 8.8% – Here’s Why

Hypermarcas (OTCMKTS:HYPMY) shares traded down 8.8% during trading on Wednesday. The company traded as low as $3.92 and last traded at $4.2142. 4,018 shares traded hands during mid-day trading, a decline of 79% from the average daily volume of 19,450 shares. The stock had previously closed at $4.62.

Analyst Upgrades and Downgrades

Separately, Jefferies Financial Group raised Hypermarcas to a “strong-buy” rating in a research note on Monday, July 20th. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy”.

Hypermarcas Price Performance

The company has a current ratio of 1.86, a quick ratio of 1.26 and a debt-to-equity ratio of 0.50. The company has a market cap of $2.97 billion, a PE ratio of 8.43 and a beta of 0.71. The firm has a 50 day moving average of $4.30 and a two-hundred day moving average of $4.32.

Hypermarcas (OTCMKTS:HYPMY) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.13 by $0.01. Hypermarcas had a return on equity of 12.68% and a net margin of 19.77%. Research analysts predict that Hypermarcas will post 0.53 earnings per share for the current fiscal year.

Hypermarcas Company Profile

Hypermarcas SA was a Brazilian consumer health and pharmaceutical company that developed, manufactured and marketed branded products for healthcare, personal care and consumer markets. Its portfolio historically included over-the-counter medicines, prescription products, vitamins, toiletries, cosmetics and other household or personal-care brands.

The company expanded through acquisitions and operated primarily in Brazil, building a broad portfolio of locally recognized brands. In the mid-2010s, Hypermarcas began divesting its non-pharmaceutical businesses to concentrate on healthcare and medicines.